This also emphasizes that the conventional clinical (such as histology, tumor size, affected lymph node, and age) and pathological (receptor status of human epidermal growth factor receptor 2 (HER2), estrogen, and progesterone) classifications do not do justice to the complexity of this disease and are therefore limited as factors in therapeutic decisions and prognosis [8,9]. Here, ERBB2 is linked to neoplasm.